球盟会·(中国)-官方网站_球盟会

Dr. Ren Li Appointed Chief Technology Officer at C...
2023.09.15
Dr. Ren Li Appointed Chief Technology Officer at C...
Cure Genetics is delighted to announce that Dr. Li Ren has joined the company recently, taking on the role of Chief Technology Officer in Cell Therapy.

More

>
Cure Genetics and Frametact Limited Enter collabor...
2023.09.14
Cure Genetics and Frametact Limited Enter collabor...
Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement.

More

>
Dr. Shawn He Named Chief Scientific Officer at Cur...
2023.08.01
Dr. Shawn He Named Chief Scientific Officer at Cur...
Cure Genetics is delighted to announce that Dr. Shawn He will officially take up his post as the Chief Scientific Officer (CSO) in cell therapy on August 1, 2023. Shawn will guide the navigation of Cure Genetics' cell therapy development, leading the team to break new ground and accelerate the progress of cell therapy pipelines.

More

>
Cure Genetics and Frametact Reach a $60 Million Co...
2023.09.14
Cure Genetics and Frametact Reach a $60 Million Co...
Cure Genetics and Frametact Limited jointly announce the signing of a collaborative development and licensing agreement. The partnership will leverage Cure Genetics' proprietary VELPTM platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases.

More

>
Robert R. Ruffolo Joins CureGenetics's Scientific ...
2022.04.01
Robert R. Ruffolo Joins CureGenetics's Scientific ...
In April 2022, Suzhou, China, Cure Genetics, a biotechnology company focusing on development of cutting-edge gene and cell therapies, announced that Dr. Robert R. Ruffolo has joined its Scientific Advisory Board (SAB). Where he will provide scientific guidance to Cure Genetics technology platform and R&D pipeline, as well as assisting the Company’s global partnership effort.

More

>
友情链接: